Prescient Therapeutics Opens SPP to Raise $7m Today
Filed with ASX · · 12 pages · English
Summary by 6ix AI
Eligible shareholders can acquire new shares at a discounted price without incurring brokerage fees. The funds will also support general working capital and business development activities. A live shareholder briefing is scheduled to discuss the SPP and its intended use of funds.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Update and Appendix 4C
- March 2026 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
Later from Prescient Therapeutics
- PTX-100 CTCL Phase 2a study reaches review milestone
- PTX Successfully Completes $6m Raise Via SPP and Placement
- September 2026 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics